NK-1 Drug Fills Motion Sickness Gap
Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.
By
Kerri Miller
January 2, 2026
Clinical Scorecard: NK-1 Drug Fills Motion Sickness Gap
At a Glance
Category Detail
Condition Motion Sickness Key Mechanisms Neurokinin-1 receptor antagonist targeting substance P pathway Target Population Adults experiencing motion-induced vomiting Care Setting Outpatient, during travel
Key Highlights
First new pharmacologic treatment for motion sickness in over 40 years Tradipitant significantly reduces vomiting incidence by 50% to 70% Favorable safety profile with common adverse reactions including somnolence and fatigue Not studied in pediatric patients or those with severe renal or hepatic impairment Ongoing development for other indications including gastroparesis Guideline-Based Recommendations
Diagnosis
Assess symptoms of motion sickness during travel Management
Prescribe tradipitant for prevention of motion-induced vomiting in adults Monitoring & Follow-up
Monitor for adverse reactions, especially somnolence and fatigue Risks
Avoid use in patients with severe renal impairment or hepatic impairment Caution with concomitant CNS depressants or strong CYP3A4 inhibitors Patient & Prescribing Data
Adults with motion sickness symptoms
Tradipitant offers effective prevention without limitations of existing therapies
Clinical Best Practices
Educate patients on potential impairment of mental and physical abilities Consider alternative therapies for patients with contraindications Monitor patients for efficacy and side effects during treatment References
